Spondyloarthritis & psoriatic arthritis
Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trial
Primary result · Simultaneous ACR50 and ≥10% weight reductionResult — go to the resultDifference Δ37.5%Authors' conclusion
Comprehensive improvements in disease activity, including ACR50, quality of life, weight, and metabolic outcomes, continued through week 52 and were greater with IXE+TZP than IXE alone, with no new safety concerns. These findings support concomitant IXE+TZP in patients with active PsA and immunometabolic disease.
Study context
- Population
- Adults with active psoriatic arthritis (PsA) and obesity or overweight with at least one weight-related comorbidityrandomized
- Participants
- 271 adults
- Comparison
- Ixekizumab (IXE)+tirzepatide (TZP) versus IXE
- IXE+TZPn = 138
- IXEn = 133
- Primary endpoint
- Simultaneous ACR50 and ≥10% weight reduction
- Follow-up
- Week 52
Methodological detailsWeek 52 outcomes were prespecified, non-multiplicity-controlled, and exploratory
- Week 52 outcomes were prespecified, non-multiplicity-controlled, and exploratory
Primary result
As reported in the abstract
Difference
Δ37.5%
P < 0.001
By group
Further findings
ACR50 · week 52 · higher with IXE+TZP
difference Δ 28.0% · P < 0.001
ACR20, minimal disease activity, Disease Activity Index for Psoriatic Arthritis, patient-reported outcomes, and metabolic outcomes · week 52
- IXE+TZP demonstrated significant improvements versus IXE alone
Original publication
Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trial. Arthritis Rheumatol. Published 11 November 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →